Although targeting PD-L1-mediated extracellular signaling pathway brings effective anti-cancer therapies, some patients have experienced rapid cancer progression during ICI immunotherapy, making it difficult for patients to benefit from clinical treatment. Here, CD274 is linked to cancer.